文献速递类风湿关节炎

类风湿关节炎患者使用传统合成、生物及靶向合成改善病情抗风湿药的主要不良心血管事件风险:德国RABBIT登记观察性数据

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
PubMed 文献 · RMD Open · 2023-01-01

基于德国RABBIT登记2017年1月至2022年4月启动的DMARD治疗片段,共14 203个治疗片段(21 218患者年)发生154例MACE。JAKi、TNFi、bDMARDs和csDMARDs的MACE发生率分别为每100患者年0.68、0.62、0.76和0.95;以TNFi为参照,JAKi、bDMARDs和csDMARDs的校正HR分别为0.89、0.76和1.36,均未达统计学显著。结论认为JAKi相比其他DMARDs并未更频繁发生MACE。

要点

  • JAKi、TNFi、bDMARDs和csDMARDs的MACE发生率分别为每100患者年0.68、0.62、0.76和0.95。
  • 以TNFi为参照,JAKi、bDMARDs和csDMARDs的校正HR分别为0.89、0.76和1.36,均未达统计学显著。
  • 巴瑞替尼、托法替布和乌帕替尼的MACE发生率分别为每100患者年0.49、0.98和0.53。

核心结论

  • 在这项德国观察性队列研究中,JAKi相比其他DMARDs并未更频繁发生MACE,但各JAKi的未校正发生率不同。

研究设计与样本

  • 队列研究分析2017年1月至2022年4月期间在生物制剂登记RABBIT中启动的DMARD治疗片段。
  • 共纳入14 203个治疗片段(21 218患者年),发生154例MACE。
  • 采用逆概率治疗加权校正的Andersen-Gill模型估计HR。

主要发现

  • JAKi、TNFi、bDMARDs和csDMARDs的MACE发生率分别为每100患者年0.68(95%CI 0.47至0.95)、0.62(0.45至0.83)、0.76(0.53至1.06)和0.95(0.68至1.29)。
  • 心血管风险患者中MACE发生率更高。
  • 总体人群中,以TNFi为参照,JAKi、bDMARDs和csDMARDs的校正HR分别为0.89(95%CI 0.52至1.52)、0.76(0.45至1.27)和1.36(0.85至2.19)。
  • 心血管风险患者中,以TNFi为参照,JAKi、bDMARDs和csDMARDs的校正HR分别为0.74(95%CI 0.41至1.31)、0.75(0.45至1.27)和1.21(0.74至1.98)。
  • 在≥65岁、有心血管病史或吸烟的患者中HR未升高,以csDMARD为参照代替TNFi时HR亦未升高。

关键数值与推荐

  • 巴瑞替尼、托法替布和乌帕替尼的MACE发生率分别为每100患者年0.49(95%CI 0.25至0.85)、0.98(0.58至1.55)和0.53(0.15至1.36)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effects of Janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), other biologic(b) or conventional synthetic(cs) disease-modifying antirheumatic drugs (DMARDs) on the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA). METHODS: Cohort study analysing episodes of DMARD-treatment initiated between January 2017 and April 2022 in the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy. Incidence rates (IRs) per 100 patient-years with 95% CIs were calculated for overall patients and those with cardiovascular risk (age ≥50 years and ≥1 cardiovascular risk factor). MACE risk was estimated as HRs by inverse probability of treatment weight-adjusted Andersen-Gill models. RESULTS: A total of 154 MACE occurred among 14 203 treatment episodes (21 218 patient-years). IRs were 0.68 (0.47; 0.95), 0.62 (0.45; 0.83), 0.76 (0.53; 1.06) and 0.95 (0.68; 1.29) for JAKi, TNFi, bDMARDs and csDMARDs, respectively. IRs were higher in cardiovascular risk patients. Adjusted HRs (95% CI) comparing JAKi, bDMARDs and csDMARDs with TNFi were 0.89 (0.52 to 1.52), 0.76 (0.45; to1.27) and 1.36 (0.85 to 2.19) in overall, and 0.74 (0.41 to 1.31), 0.75 (0.45 to 1.27) and 1.21 (0.74 to 1.98) in cardiovascular risk patients. HRs were not increased in patients ≥65 years, with cardiovascular history or smokers, and also not when using csDMARD as reference instead of TNFi. IRs for baricitinib, tofacitinib and upadacitinib were 0.49 (0.25 to 0.85), 0.98 (0.58 to 1.55) and 0.53 (0.15 to 1.36), respectively. CONCLUSION: In this German observational cohort study, MACE did not occur more frequently with JAKi compared with other DMARDs. However, individual JAKis showed different unadjusted IRs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Meissner Y, Schäfer M, Albrecht K, et al. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. RMD Open. 2023. PMID: 37880180. doi:10.1136/rmdopen-2023-003489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。